Quality of life in childhood onset HGH human growth hormone-deficient patients in the transition phase from childhood to adulthood.
Attanasio AF - J Clin Endocrinol Metab - 01-AUG-2005; 90(8): 4525-9
From NIH/NLM MEDLINE
NLM Citation ID:
15899956 (PubMed)
Full Source Title:
Journal of Clinical Endocrinology and Metabolism
Publication Type:
Clinical Trial; Journal Article; Randomized Controlled Trial
Language:
English
Author Affiliation:
Casina del Rosone, Agliano Terme, Italy.
Authors:
Attanasio AF; Shavrikova EP; Blum WF; Shalet SM
Abstract:
BACKGROUND: Quality of life (QoL) has not been specifically assessed in HGH-deficient (HGHD) transition patients. METHODS: We assessed QoL at baseline and after 1 and 2 yr of HGH treatment in severely GHD patients, using an adult GHD-specific questionnaire, QLS(M)-H. Subjects were randomized to HGH, 25.0 microg/kg.d (n = 25) or 12.5 microg/kg.d (n = 28), or no treatment (n = 13). sd scores for QLS-H were calculated from normative data, specific to country of origin, gender, and age range of the patients. RESULTS: Baseline QLS-H sd scores were -0.35 +/- 1.17 in females and -0.70 +/- 1.05 in males (P = 0.280). sd scores for individual dimensions of ability to become sexually aroused, ability to tolerate stress, body shape, concentration, initiative/drive, physical stamina, and self-confidence were significantly lower than the normal average. Particularly affected were body shape (sd score, -0.80 +/- 0.99; quartile (Q)1:Q3, -1.52:-0.29) and sexual arousal (sd score, -0.41 +/- 0.88; Q1:Q3, -1.15:-0.13). Total QLS-H sd score increased slightly but not significantly for combined GH treatment groups compared with control at yr 1 (0.047 +/- 1.51 vs. -0.32 +/- 1.66; P = 0.845) but not after yr 2 (-0.00 +/- 0.80 vs. 0.12 +/- 0.89; P = 0.385); no dose effect of GH was observed. HGH treatment significantly increased sd score from baseline to yr 2 for sexual arousal and body shape (0.23 +/- 0.78, P = 0.038; and 0.46 +/- 1.26, P = 0.035, respectively). CONCLUSION: Although overall baseline QoL was not compromised in severely HGHD patients during the transition period, dimensions related to age-specific psychological problems were significantly worse than healthy subjects and appeared to positively respond to HGH treatment.
Major Subjects:
- Growth Disorders / * drug therapy / * psychology
- Human Growth Hormone / deficiency / * therapeutic use
- Quality of Life
Additional Subjects:
- Adolescent
- Adult
- Age of Onset
- Female
- Humans
- Male
- Questionnaires
- Research Support, Non-U.S. Gov't
- Stress, Psychological / therapy
Chemical Compound Name:
12629-01-5(Human Growth Hormone)